Agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-12-12 and is reviewed periodically as new material appears.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Uterine prolapse occurs when there is a disruption to any of the structures mentioned above that help hold the uterus in place. Weakening of the levator ani muscles can occur during vaginal childbirth, in which portions of the muscle can detach from the bony pelvis, or through age-related changes to musculature, and this can lead to a loss of support for the uterus. Pregnancy, vaginal childbirth, or injury can also stretch and weaken the uterosacral ligaments, leading to poor suspension or positioning of the uterus so that it is no longer supported by pelvic floor muscles. Problems with the vaginal wall, such as trauma or loss of smooth muscle support in the wall, can lead to the uterus collapsing downward due to a loss of support. When the uterus prolapses, it also drags the upper portion of the vagina (the apical vagina) along with it due to its anatomic relationship with the apical vagina. Additionally, the pelvic musculature and connective tissues are estrogen sensitive and respond to changes in estrogen level. Estrogen deficiency, which can occur during menopause, can affect the production of collagen that is needed to build connective tissue that makes up ligaments and fascia, which can contribute to uterine prolapse. This is also a reason that connective tissue disorders can predispose certain people to uterine prolapse.
== Sponsorship == In April 2022, the team announced their sponsorship with car retailer Cazoo starting in July 2022. The Cazoo brand is visible on the front of the new jerseys as the team's main sponsor. In addition to the Bundesliga professionals, Cazoo appeared as shirt sponsor and advertising partner of the second team of SC Freiburg in the third division and as co-sponsor of the Freiburg Football School, and became visible at all matches of the SC junior teams. Cazoo also became a co-sponsor and sleeve sponsor of SC Freiburg's Bundesliga women.
Wholesaler: A merchant intermediary who sells chiefly to retailers, other merchants, or industrial, institutional, and commercial users mainly for resale or business use. The transactions are B2B (Business to Business). Wholesalers typically sell in large quantities. (Wholesalers, by definition, do not deal directly with the public). Retailer: A merchant intermediary who sells direct to the public. There are many different types of retail outlet - from hypermarts and supermarkets to small, independent stores. The transactions in this case are B2C (Business to Customer). Agent: An intermediary who is authorized to act for a principal in order to facilitate exchange. Unlike merchant wholesalers and retailers, agents do not take title to goods, but simply put buyers and sellers together. Agents are typically paid via commissions by the principal. For example, travel agents are paid a commission of around 15% for each booking made with an airline or hotel operator. Jobber: A special type of wholesaler, typically one who operates on a small scale and sells only to retailers or institutions. For example, rack jobbers are small independent wholesalers who operate from a truck, supplying convenience stores with snack foods and drinks on a regular basis.
Sources: en.wikipedia.org
{\displaystyle G^{*}+M\to M^{+\bullet }+e^{-}+G} where G is the excited state species (indicated by the superscripted asterisk), and M is the species that is ionized by the loss of an electron to form the radical cation (indicated by the superscripted "plus-dot"). Penning ionization refers to the interaction between a gas-phase excited-state atom or molecule G* and a target molecule M resulting in the formation of a radical molecular cation M+., an electron e−, and a neutral gas molecule G: G ∗ + M → M + ∙ + e − + G {\displaystyle G^{*}+M\to M^{+\bullet }+e^{-}+G} Penning ionization occurs when the target molecule has an ionization potential lower than the internal energy of the excited-state atom or molecule. Associative Penning ionization can also occur: G ∗ + M → M G + ∙ + e − {\displaystyle G^{*}+M\to MG^{+\bullet }+e^{-}} There are many important dissociation reactions that take place in the gas phase.
=== Chemical properties === Technetium is located in group 7 of the periodic table, between rhenium and manganese. As predicted by the periodic law, its chemical properties are between those two elements. Of the two, technetium more closely resembles rhenium, particularly in its chemical inertness and tendency to form covalent bonds. This is consistent with the tendency of period 5 elements to resemble their counterparts in period 6 more than period 4 due to the lanthanide contraction. Unlike manganese, technetium does not readily form cations (ions with net positive charge). Technetium exhibits nine oxidation states from −1 to +7, with +4, +5, and +7 being the most common. Technetium dissolves in aqua regia, nitric acid, and concentrated sulfuric acid, but not in hydrochloric acid of any concentration. Metallic technetium slowly tarnishes in moist air and, in powder form, burns in oxygen. When reacting with hydrogen at high pressure, it forms the non-stoichiometric hydride TcH1.3 and while reacting with carbon it forms Tc6C, with cell parameter 0.398 nm. Technetium can catalyse the destruction of hydrazine by nitric acid, and this property is due to its multiplicity of valencies. This caused a problem in the separation of plutonium from uranium in nuclear fuel processing, where hydrazine is used as a protective reductant to keep plutonium in the trivalent rather than the more stable tetravalent state. The problem was exacerbated by the mutually enhanced solvent extraction of technetium and zirconium at the previous stage, and required a process modification.
Covalent immobilization of a metal-containing catalytic moiety by an irreversible reaction with the protein; Supramolecular interactions between a protein and a high-affinity substrate could be used to anchor a metal cofactor; The metal substitution in a natural metalloenzyme can result in a novel catalytic activity to the protein. The metal could be part of a prosthetic group (e.g., heme) or bound to amino acids; Amino acids with Lewis-basic properties in a hydrophobic pocket could interact with coordinatively unsaturated metal center. These four strategies led to a great progress in the field of artificial metalloenzymes since the beginning of the 21st century, unlocking exceptional selectivity for new-to-nature reactions.
In 2016, Burger King signed a build-to-suit lease agreement on a new 150,000 square feet (14,000 m2) five-story headquarters building to be built at 5707 Blue Lagoon Drive, just down the street from its existing nine-story headquarters at 5505 Blue Lagoon Drive. This was slightly smaller than the 200,000 square feet (19,000 m2) it was leasing in its current headquarters building at the time. In 2018, Burger King moved into its new headquarters at 5707 Blue Lagoon Drive. As of August 2024, the Burger King system operates more than 18,700 locations in more than 100 countries and U.S. territories.
Sources: en.wikipedia.org
Lime can be manufactured in countercurrent furnaces allowing the heat to reach high temperatures using low cost, low temperature burning fuel. Historically this was developed by the Japanese in certain types of the Anagama kiln. The kiln is built in stages, where fresh air coming to the fuel is passed downwards while the smoke and heat is pushed up and out. The heat does not leave the kiln, but is transferred back to the incoming air, and thus slowly builds up to 3,000 °C (5,430 °F) and more.
Tuttle (1857), first bishop of the Episcopal Diocese of Idaho, Montana, and Utah William David Walker (1859), first bishop of the Episcopal Diocese of North Dakota Henry Y. Satterlee (1863), first bishop of the Episcopal Diocese of Washington; established the Washington National Cathedral Bernard Drachman (1882), leader of Orthodox Judaism; former president of the Orthodox Union Leon Harrison (1886), rabbi of Temple Israel in St. Louis Herbert Shipman (1890), Suffragan bishop in the Episcopal Diocese of New York Stephen Samuel Wise (1892), rabbi and Zionist leader Frederick Herbert Sill (1895), Anglican monk and founder of the Kent School Henry S. Whitehead (1904), rector, and author of horror fiction Vedder Van Dyck (1918), fifth bishop in the Episcopal Diocese of Vermont Walter M. Higley (1922), sixth bishop of the Episcopal Diocese of Central New York M. Moran Weston (1930), Episcopal priest, social activist, and businessman who co-founded Carver Federal Savings Bank Arthur Lelyveld (1933), rabbi, president of the American Jewish Congress and first Jewish editor-in-chief of the Columbia Daily Spectator Moshe Davis (1936), rabbi and founder of Camp Ramah Paul van K.
Red blood cell autoantibodies tend to be specific for red cell antigens of high frequency within the population. An antibody elution can aid in the identification of clinically significant alloantibodies when autoantibodies interfere with the antibody identification process.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
It is frequently described as an MC4 receptor agonist, but binding assays show activity at more than one melanocortin subtype. Selectivity is therefore relative rather than absolute. This matters when interpreting side effects tied to other receptor subtypes.